Resistance of mitochondrial p53 to dominant inhibition

被引:22
作者
Heyne, Kristina [1 ]
Schmitt, Katrin [1 ]
Mueller, Daniel [1 ]
Armbruester, Vivienne [1 ]
Mestres, Pedro
Roemer, Klaus [1 ]
机构
[1] Univ Saarland, Sch Med, Jose Carreras Res Ctr, D-66421 Homburg, Germany
关键词
D O I
10.1186/1476-4598-7-54
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Mutation of a tumor suppressor allele leaves the second as backup. Not necessarily so with p53. This homo-tetrameric transcription factor can become contaminated with mutant p53 through hetero-tetramerization. In addition, it can be out-competed by the binding to p53 DNA recognition motifs of transactivation-incompetent isoforms (Delta N and Delta TA-isoforms) of the p53/p63/p73 family of proteins. Countermeasures against such dominant-negative or dominant-inhibitory action might include the evolutionary gain of novel, transactivation-independent tumor suppressor functions by the wild-type monomer. Results: Here we have studied, mostly in human HCT116 colon adenocarcinoma cells with an intact p53 pathway, the effects of dominant-inhibitory p53 mutants and of Delta ex2/3p73, a tumor-associated Delta TA-competitor of wild-type p53, on the nuclear transactivation-dependent and extranuclear transactivation-independent functions of wild-type p53. We report that mutant p53 and Delta ex2/3p73, expressed from a single gene copy per cell, interfere with the stress-induced expression of p53-responsive genes but leave the extra-nuclear apoptosis by mitochondrial p53 largely unaffected, although both wild-type and mutant p53 associate with the mitochondria. In accord with these observations, we present evidence that in contrast to nuclear p53 the vast majority of mitochondrial p53, be it wild-type or mutant, is consisting of monomeric protein. Conclusion: The extra-nuclear p53-dependent apoptosis may constitute a fail-safe mechanism against dominant inhibition.
引用
收藏
页数:17
相关论文
共 52 条
[1]   Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria [J].
Arima, Y ;
Nitta, M ;
Kuninaka, S ;
Zhang, DW ;
Fujiwara, T ;
Taya, Y ;
Nakao, M ;
Saya, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (19) :19166-19176
[2]  
Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO
[3]  
2-6
[4]   Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome [J].
Birch, JM ;
Blair, V ;
Kelsey, AM ;
Evans, DG ;
Harris, M ;
Tricker, KJ ;
Varley, JM .
ONCOGENE, 1998, 17 (09) :1061-1068
[5]   p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect [J].
Blagosklonny, MV .
FASEB JOURNAL, 2000, 14 (13) :1901-1907
[6]   Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein [J].
Boese, A ;
Sauter, M ;
Galli, U ;
Best, B ;
Herbst, H ;
Mayer, J ;
Kremmer, E ;
Roemer, K ;
Mueller-Lantzsch, N .
ONCOGENE, 2000, 19 (38) :4328-4336
[7]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[8]   Requirement for p53 and p21 to sustain G2 arrest after DNA damage [J].
Bunz, F ;
Dutriaux, A ;
Lengauer, C ;
Waldman, T ;
Zhou, S ;
Brown, JP ;
Sedivy, JM ;
Kinzler, KW ;
Vogelstein, B .
SCIENCE, 1998, 282 (5393) :1497-1501
[9]   How many mutant p53 molecules are needed to inactivate a tetramer? [J].
Chan, WM ;
Siu, WY ;
Lau, A ;
Poon, RYC .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (08) :3536-3551
[10]   Dissecting p53-dependent apoptosis [J].
Chipuk, J. E. ;
Green, D. R. .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (06) :994-1002